Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Advanced biliary tract cancer (BTC) is associated with poor survival. A recent phase II study of triplet combination chemotherapy, including gemcitabine, cisplatin, and nanoparticle albumin-bound (nab)-paclitaxel, has shown promising results. This study aimed to compare the efficacy of triplet and standard doublet chemotherapy in a real-world setting. Methods: Patients with advanced BTC treated with triplet and doublet chemotherapy regimens were recruited. The propensity-score nearest neighbor matching method with a ratio of oneto- one was used to create a matched cohort for comparison. Progression-free survival (PFS), overall survival (OS), and safety profiles were examined in both groups. Results: A total of 68 patients (n=34 per group) were included in the matched cohort, and their baseline characteristics were well balanced. Survival outcomes in the triplet chemotherapy group were not better than those in the doublet chemotherapy group, with a median PFS of 7.5 months (95% confidence interval [CI], 4.1 to 10.9) versus 7.2 months (95% CI, 5.6 to 8.9) (hazard ratio [HR], 0.93; 95% CI, 0.53 to 1.62; p=0.793) and a median OS of 13.7 months (95% CI, 8.8 to 18.7) versus 12.2 months (95% CI, 8.4 to 16.0) (HR 0.73; 95% CI, 0.38 to 1.41; p=0.354), respectively. In addition, the treatment-related severe adverse events, such as neutropenia, were more common in the triplet chemotherapy group. Conclusions: Gemcitabine, cisplatin, and nab-paclitaxel did not improve the PFS or OS compared to that achieved by standard chemotherapy in patients with advanced BTC. The benefits of triplet chemotherapy in advanced BTC require examination in large randomized controlled trials.
Abstract
Background/Aims: Advanced biliary tract cancer (BTC) is associated with poor survival. A recent phase II study of triplet combination chemotherapy, including gemcitabine, cisplatin, and nanoparticle albumin-bound (nab)-paclitaxel, has shown promising results. This study aimed to compare the efficacy of triplet and standard doublet chemotherapy in a real-world setting. Methods: Patients with advanced BTC treated with triplet and doublet chemotherapy regimens were recruited. The propensity-score nearest neighbor matching method with a ratio of oneto- one was used to create a matched cohort for comparison. Progression-free survival (PFS), overall survival (OS), and safety profiles were examined in both groups. Results: A total of 68 patients (n=34 per group) were included in the matched cohort, and their baseline characteristics were well balanced. Survival outcomes in the triplet chemotherapy group were not better than those in the doublet chemotherapy group, with a median PFS of 7.5 months (95% confidence interval [CI], 4.1 to 10.9) versus 7.2 months (95% CI, 5.6 to 8.9) (hazard ratio [HR], 0.93; 95% CI, 0.53 to 1.62; p=0.793) and a median OS of 13.7 months (95% CI, 8.8 to 18.7) versus 12.2 months (95% CI, 8.4 to 16.0) (HR 0.73; 95% CI, 0.38 to 1.41; p=0.354), respectively. In addition, the treatment-related severe adverse events, such as neutropenia, were more common in the triplet chemotherapy group. Conclusions: Gemcitabine, cisplatin, and nab-paclitaxel did not improve the PFS or OS compared to that achieved by standard chemotherapy in patients with advanced BTC. The benefits of triplet chemotherapy in advanced BTC require examination in large randomized controlled trials.
참고문헌 (26)
- Banales JM, "Expert consensus document : cholangiocarcinoma : current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma(ENS-CCA)", Nat Rev Gastroenterol Hepatol, 13, pp.261~280 (2016)
- Saha SK, "Forty-year trends in cholangiocarcinoma incidence in the U. S. : intrahepatic disease on the rise", Oncologist, 21, pp.594~599 (2016)
- Florio AA, "Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012", Cancer, 126, pp.2666~2678 (2020)
- Sung H, "Global Cancer Statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- Siegel RL, "Cancer statistics, 2021", CA Cancer J Clin, 71, pp.7~33 (2021)
- DeOliveira ML, "Cholangiocarcinoma : thirty-one-year experience with 564 patients at a single institution", Ann Surg, 245, pp.755~762 (2007)
- Hyder O, "A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma : an Eastern and Western experience", JAMA Surg, 149, pp.432~438 (2014)
- Komaya K, "Recurrence after resection with curative intent for distal cholangiocarcinoma", Br J Surg, 104, pp.426~433 (2017)
- Jeong S, "Risk stratification system to predict recurrence of intrahepatic cholangiocarcinoma after hepatic resection", BMC Cancer, 17, pp.464~ (2017)
- Komaya K, "Recurrence after curative-intent resection of perihilar cholangiocarcinoma : analysis of a large cohort with a close postoperative followup approach", Surgery, 163, pp.732~738 (2018)
- Valle J, "Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer", N Engl J Med, 362, pp.1273~1281 (2010)
- Valle JW, "Cisplatin and gemcitabine for advanced biliary tract cancer : a meta-analysis of two randomised trials", Ann Oncol, 25, pp.391~398 (2014)
- Kim BJ, "Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin : retrospective analysis of 740 patients", Cancer Chemother Pharmacol, 80, pp.209~215 (2017)
- Sahai V, "Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma : a phase 2 clinical trial", JAMA Oncol, 4, pp.1707~1712 (2018)
- Sakai D, "Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)", Ann Oncol, 29, pp.viii205~ (2018)
- Morizane C, "Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced", recurrent biliary tract cancer : the FUGA-BT(JCOG1113)randomized phase III clinical trial, 2019, pp.30, 1950~1958
- Phelip JM, "Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer : results of AMEBICA PRODIGE 38 randomized phase II trial", Ann Oncol, 31, pp.S260~S261 (2020)
- ShroffRT, "Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers : a phase 2 clinical trial", JAMA Oncol, 5, pp.824~830 (2019)
- Bergquist JR, "Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma : a national cohort analysis", J Surg Oncol, 114, pp.475~482 (2016)
- Tella SH, "Novel staging system using carbohydrate antigen(CA)19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival", Eur J Surg Oncol, 46, pp.789~795 (2020)
- Lamarca A, "Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials", J Natl Cancer Inst, 112, pp.200~210 (2020)
- McNamara MG, "Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer", J Hepatol, 73, pp.1109~1117 (2020)
- Nakamura H, "Genomic spectra of biliary tract cancer", Nat Genet, 47, pp.1003~1010 (2015)
- Javle M, "Biliary cancer : utility of next-generation sequencing for clinical management", Cancer, 122, pp.3838~3847 (2016)
- Wardell CP, "Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations", J Hepatol, 68, pp.959~969 (2018)
- Casadio M, "Molecular landscape and therapeutic strategies in cholangiocarcinoma : an integrated translational approach towards precision medicine", Int J Mol Sci, 22, pp.5613~ (2021)